umifenovir (arbidol) - versus lopinavir/ritonavir - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

viral clearance by day 14 1.84 [0.40, 8.38]> 10%1 study (1/-)78.4 %NAnot evaluable important-
viral clearance by day 7 1.08 [0.41, 2.89]> 10%1 study (1/-)56.3 %NAnot evaluable important-
severe COVID-19 occurrence 0.30 [0.07, 1.27]< 10%1 study (1/-)94.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.